High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis b virus recurrence after liver transplantation: A systematic review

American Journal of Transplantation

Volumn 13, Issue 2, 2013, Pages 353-362

  Cholongitas, E ^a   Papatheodoridis, G V ^b  

^a ARISTOTLE UNIVERSITY MEDICAL SCHOOL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

entecavir; Hepatitis B immunoglobulin; lamivudine; liver transplantation; recurrence HBV infection; tenofovir

Indexed keywords

ADEFOVIR DIPIVOXIL; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; LAMIVUDINE; NUCLEOSIDE ANALOG; TENOFOVIR; VIRUS DNA;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; GENETIC ANALYSIS; GRAFT RECIPIENT; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MONOTHERAPY; MULTICENTER STUDY; PATIENT SELECTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT INFECTION; SYSTEMATIC REVIEW (TOPIC); TREATMENT RESPONSE; VIRUS STRAIN;

ADENINE; ANTIVIRAL AGENTS; DNA, VIRAL; GUANINE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; IMMUNOGLOBULINS; LIVER FAILURE; LIVER TRANSPLANTATION; NUCLEOTIDES; ORGANOPHOSPHONATES; RECURRENCE; TIME FACTORS; TREATMENT OUTCOME;

EID: 84873078089     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04315.x     Document Type: Article

References (69)

1. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
2. EASL Clinical Practice guidelines: Management of chronic hepatitis B virus infection. J Hepatol 2012; 57: 167-185.
3. Papatheodoridis GV, Sevastianos V, Burroughs AK,. Prevention of and treatment for hepatitis B virus infection after liver transplantation in the nucleoside analogues era. Am J Transplant 2003; 3: 250-258.
4. Papatheodoridis GV, Cholongitas E, Archimandritis AJ, Burroughs AK,. Current management of hepatitis B virus infection before and after liver transplantation. Liver Int 2009; 29: 1294-1305.
5. Samuel D,. Management of hepatitis B in liver transplantation patients. Semin Liver Dis 2004; 24 (Suppl 1): 55-62.
6. Cholongitas E, Goulis J, Akriviadis E, Papatheodoridis GV,. Hepatitis B immunoglobulin and/or nucleos(t)ide analogues for prophylaxis against hepatitis b virus recurrence after liver transplantation: A systematic review. Liver Transpl 2011; 17: 1176-1190.
7. Xi ZF, Xia Q, Zhang JJ, et al. The role of entecavir in preventing hepatitis B recurrence after liver transplantation. J Dig Dis 2009; 10: 321-327.
8. Saab S, Desai S, Tsaoi D, et al. Posttransplantation hepatitis B prophylaxis with combination oral nucleoside and nucleotide analog therapy. Am J Transplant 2011; 11: 511-517.
9. Ishigami M, Onishi Y, Ito T, et al. Anti-hepatitis B surface immunoglobulin reduction in early postoperative period after liver transplantation in hepatitis B virus-positive patients. Hepatol Res 2011; 41: 1189-1198.
10. Teperman L, Spivey J, Poordad F, et al. Emtricitabine/tenofovir DF combination +/- HBIG post orthopic liver transplantation to prevent hepatitis B recurrence in patients with normal to moderate renal impairment: interim results. J Hepatol 2010; 52: S12-S13.
11. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E,. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14: 479-487.
12. Degertekin B, Han SH, Keeffe EB, et al. Impact of virologic breakthrough and HBIG regimen on Hepatitis B recurrence after liver transplantation. Am J Transplant 2010; 10: 1823-1833.
13. Jimenez-Perez M, Saez-Gomez AB, Mongil PL, Lozano-Rey JM, de LC-L, Rodrigo-Lopez JM,. Efficacy and safety of entecavir and/or tenofovir for prophylaxis and treatment of hepatitis B recurrence post-liver transplant. Transplant Proc 2010; 42: 3167-3168.
14. Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH,. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant 2012; 26: 208-215.
15. Xie SB, Zhu JY, Ying Z, Zeng LJ, Chao M, Lu MQ,. Prevention and risk factors of the HBV recurrence after orthotopic liver transplantation: 160 cases follow-up study. Transplantation 2010; 90: 786-790.
16. Campos-Varela I, Castells L, Buti M, et al. Does pre-liver transplant HBV DNA level affect HBV recurrence or survival in liver transplant recipients receiving HBIg and nucleos(t)ide analogues? Ann Hepatol 2011; 10: 180-187.
17. Wesdorp DJ, Knoester M, Coenraad MJ, Braat AE, Claas EC, van Hoek B,. One year results or tenofovir and emtricitabine without HBIG to prevent hepatitis B recurrence after liver transplantation. J Hepatol 2012; 56: S96-S97.
18. Perrillo R, Buti M, Durand F, et al. Safety and efficacy of entecavir in patients receiving liver transplantation due to chronic hepatitis B. J Hepatol 2012; 56: S212.
19. Ahn J, Cohen SM,. Prevention of hepatitis B recurrence in liver transplant patients using oral antiviral therapy without long-term hepatitis B immunoglobulin. Hepat Mon 2011; 11: 638-645.
20. Fung J, Cheung C, Chan SC, et al. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
21. Todd SR, Shiffman ML, Kimmel M, et al. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012; 32: 1138-1145.
22. Hu TH, Chen CL, Wang CC, et al. Pre-transplant HBV viral resistance is not a risk factor for HBV recurrence after liver transplantation. Liver Transpl 2012; 18 (Suppl. 1): S174.
23. Wadhawan M, Vij V, Goyal N, Dargan P, Rastogi M, Vasu F,. Living related liver transplant (LRLT) in HBV DNA negative cirrhosis without hepatitis B immune globulin (HBIG). Hepatol Int 2011; 5: S38.
24. Fung J, Chan S, Cheung C, et al. Entecavir versus Lamivudine Prophylaxis without Hepatitis B immune globulin after liver transplantation for Chronic Hepatitis B. Liver Transpl 2012; 18 (Suppl. 1): S124.
25. Ueda Y, Marusawa H, Kaido T, et al. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res 2012; in press.
26. Saraf N, Saigal S, Mohanka R, et al. Newer potent nucleos(t)ide analogues with low dose hepatitis B immunoglobulin can eliminate HBV recurrence after LT. Liver Transpl 2011; 17: S235-S236.
27. Park SJ, Paik SW, Choi MS, et al. Is lamivudine with 1-week HBlg as effective as long-term high-dose HBlg in HBV prophylaxis after liver transplantation? Transplant Proc. 2002; 34: 1252-1254.
28. Buti M, Mas A, Prieto M, et al. Adherence to lamivudine after an early withdrawal of hepatitis B immune globulin plays an important role in the long-term prevention of hepatitis B virus recurrence. Tranplantation. 2007; 84: 650-654.
29. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E,. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
30. Markowitz JS, Martin P, Conrad AJ, et al. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
31. Yoshida EM, Erb SR, Partovi N, et al. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg. 1999; 5: 520-525.
32. McCaughan GW, Spencer J, Koorey D, et al. Lamivudine therapy in patients undergoing liver transplantation for hepatitis B virus precore mutant-associated infection: High resistance rates in treatment of recurrence but universal prevention if used as prophylaxis with very low dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 512-519.
33. Angus PW, McCaughan GW, Gane EJ, Crawford DH, Harley H,. Combination low-dose hepatitis B immune globulin and lamivudine therapy provides effective prophylaxis against posttransplantation hepatitis B. Liver Transpl 2000; 6: 429-433.
34. Marzano A, Salizzoni M, Debernardi-Venon W, et al. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol. 2001; 34: 903-910.
35. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O,. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003; 3: 999-1002.
36. Ferretti G, Merli M, Ginanni CS, et al. Low-dose intramuscular hepatitis B immune globulin and lamivudine for long-term prophylaxis of hepatitis B recurrence after liver transplantation. Transplant Proc 2004; 36: 535-538.
37. Caccamo L, Romeo R, Rossi G, et al. No hepatitis recurrence using combination prophylaxis in HBV-positive liver transplant recipients with YMDD mutants. Transpl Int 2005; 18: 186-192.
38. Gane EJ, Angus PW, Strasser S, et al. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
39. Takaki A, Yagi T, Iwasaki Y, et al. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Tranplantation 2007; 83: 231-233.
40. Freshwater DA, Dudley T, Cane P, Mutimer DJ,. Viral persistence after liver transplantation for hepatitis B virus: A cross-sectional study. Transplantation 2008; 85: 1105-1111.
41. Woo HY, Choi JY, Jang JW, et al. Role of long-term lamivudine treatment of hepatitis B virus recurrence after liver transplantation. J Med Virol 2008; 80: 1891-1899.
42. Jiang L, Yan L, Li B, et al. Prophylaxis against hepatitis B recurrence posttransplantation using Lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10: 1861-1869.
43. Yao FY, Osorio RW, Roberts JP, et al. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-496.
44. Rosenau J, Bahr MJ, Tillmann HL, et al. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
45. Honaker MR, Shokouh-Amiri MH, Vera SR, et al. Evolving experience of hepatitis B virus prophylaxis in liver transplantation. Transpl Infect Dis. 2002; 4: 137-143.
46. Steinmuller T, Seehofer D, Rayes N, et al. Increasing applicability of liver transplantation for patients with hepatitis B-related liver disease. Hepatology. 2002; 35: 1528-1535.
47. Sousa JM, Pareja F, Serrano J, et al. Comparison between levels of anti-HBS with a fixed administration dose of HBIG and a combination of HBIG and lamivudine for the prophylaxis of hepatitis B after liver transplantation. Transplant Proc. 2003; 35: 723-724.
48. Ben-Ari Z, Mor E, Bar-Nathan N, Shaharabani E, Shapira Z, Tur-Kaspa R,. Combination hepatitis B immune globulin and lamivudine versus hepatitis B immune globulin monotherapy in preventing recurrent hepatitis B virus infection in liver transplant recipients. Transplant Proc. 2003; 35: 609-611.
49. Zhu JP, Zhang TL, Li L, et al. Prevention and treatment of hepatitis B recurrence after liver transplantation. HPDI 2003; 2: 500-503.
50. Marzano A, Lampertico P, Mazzaferro V, et al. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-538.
51. Zheng S, Chen Y, Liang T, et al. Prevention of hepatitis B recurrence after liver transplantation using lamivudine or lamivudine combined with hepatitis B Immunoglobulin prophylaxis. Liver Transpl 2006; 12: 253-258.
52. Karademir S, Astarcioǧlu H, Akarsu M, et al. Prophylactic use of low-dose, on-demand, intramuscular hepatitis B immunoglobulin and lamivudine after liver transplantation. Transplant Proc 2006; 38: 579-583.
53. Anderson RD, Chinnakotla S, Guo L, Perrillo RP, Klintmalm GB, Davis GL,. Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimens. Clin Transplant 2007; 21: 510-517.
54. Yi NJ, Suh KS, Cho JY, et al. Recurrence of hepatitis B is associated with cumulative corticosteroid dose and chemotherapy against hepatocellular carcinoma recurrence after liver transplantation. Liver Transpl 2007; 13: 451-458.
55. Yoshida H, Kato T, Levi DM, et al. Lamivudine monoprophylaxis for liver transplant recipients with non-replicating hepatitis B virus infection. Clin Transplant 2007; 21: 166-171.
56. Wong SN, Chu CJ, Wai CT, et al. Low risk of hepatitis B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transpl 2007; 13: 374-381.
57. Zimmerman MA, Ghobrial RM, Tong MJ, Hiatt JR, Cameron AM, Busuttil RW,. Antiviral prophylaxis and recurrence of hepatocellular carcinoma following liver transplantation in patients with hepatitis B. Transplant Proc 2007; 39: 3276-3280.
58. Akyildiz M, Karasu Z, Zeytunlu M, Aydin U, Ozacar T, Kilic M,. Adefovir dipivoxil therapy in liver transplant recipients for recurrence of hepatitis B virus infection despite lamivudine plus hepatitis B immunoglobulin prophylaxis. J Gastroenterol Hepatol 2007; 22: 2130-2134.
59. Lu A, Lu AW, Zheng SS, Wu MP, Shen Y, Yang RW,. Reevaluation of the effect of lamivudine therapy preoperative to prevent HBV recurrence after liver transplantation. Hepatobiliary Pancreat Dis Int 2008; 7: 357-361.
60. Avolio AW, Nure E, Pompili M, et al. Liver transplantation for hepatitis B virus patients: long-term results of three therapeutic approaches. Transplant Proc 2008; 40: 1961-1964.
61. Giusto M, Gentilli, Loria, et al. Combined therapy with low dose hepatitis B immunoglobulin (HBIG) and lamivudine (LAM) in patients transplanted for HBV chronic liver disease: Long term efficacy and costs. J Hepatol 2008; 48 (Suppl 2): S84.
62. Wang ZX, Fu ZR, Ding GS, et al. Prevention of hepatitis B virus reinfection after orthotopic liver transplantation. Transplant Proc 2004; 36: 2315-2317.
63. Loomba R, Rowley AK, Wesley R, et al. Hepatitis B immunoglobulin and Lamivudine improve hepatitis B-related outcomes after liver transplantation: meta-analysis. Clin Gastroenterol Hepatol 2008; 6: 696-700.
64. Katz LH, Paul M, Guy DG, Tur-Kaspa R,. Prevention of recurrent hepatitis B virus infection after liver transplantation: hepatitis B immunoglobulin, antiviral drugs, or both? Systematic review and meta-analysis. Transpl Infect Dis 2010; 12: 292-308.
65. Rao W, Wu X, Xiu D,. Lamivudine or lamivudine combined with hepatitis B immunoglobulin in prophylaxis of hepatitis B recurrence after liver transplantation: A meta-analysis. Transpl Int 2009; 22: 387-394.
66. Zoulim F,. Hepatitis B virus resistance to antiviral drugs: where are we going? Liver Int 2011; 31 (Suppl 1): 111-116.
67. Ayoub WS, Keeffe EB,. Review article: Current antiviral therapy of chronic hepatitis B. Aliment Pharmacol Ther 2011; 34: 1145-1158.
68. Papatheodoridis GV, Dimou E, Dimakopoulos K, et al. Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-129.
69. Lenci I, Tisone G, Di PD, et al. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55: 587-593.